RxDoctor Payments Data

Megan Campbell

Psychiatric/Mental Health · Coldwater, MINPI 1326440090

Payments from drug & device makers

$1,670in general payments, 2019–2025

Across 118 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$302
  • Otsuka America Pharmaceutical, Inc.$265
  • Alkermes, Inc.$244
  • Lundbeck LLC$196
  • Mindray DS USA, Inc.$113
  • Johnson & Johnson$108
  • plus $443 from 9 others

What the payments were for

  • Food & beverage$1,62397%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,670 in reported general payments places this provider in the 70th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$5,631
Medicare patients
24
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole116$185,785
Abilify MaintenaAripiprazole16$42,356
VraylarCariprazine Hcl26$38,590
Invega SustennaPaliperidone Palmitate16$35,850
FanaptIloperidone18$33,750
TrintellixVortioxetine Hydrobromide47$23,556
CaplytaLumateperone Tosylate13$20,571
Asenapine Maleate13$6,075
Vilazodone Hcl35$3,673
Quetiapine Fumarate ErQuetiapine Fumarate38$3,450
Ziprasidone Hcl27$2,777
Oxcarbazepine42$2,163
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,464
Aripiprazole14$1,274
Olanzapine37$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$265$228,140132 claims
AbbVieVraylar$46$38,59026 claims
Johnson & JohnsonInvega Sustenna$108$35,85016 claims
Vanda Pharmaceuticals Inc.Fanapt$28$33,75018 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$69$23,55647 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$302$20,57113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Coldwater

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →